CN102482281A - 吡咯并[2，3-d]嘧啶衍生物 - Google Patents

吡咯并[2，3-d]嘧啶衍生物 Download PDF

Info

Publication number
CN102482281A
CN102482281A CN2010800334905A CN201080033490A CN102482281A CN 102482281 A CN102482281 A CN 102482281A CN 2010800334905 A CN2010800334905 A CN 2010800334905A CN 201080033490 A CN201080033490 A CN 201080033490A CN 102482281 A CN102482281 A CN 102482281A
Authority
CN
China
Prior art keywords
group
cancer
compound
hydrogen atom
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800334905A
Other languages
English (en)
Chinese (zh)
Inventor
坪池一成
水野玄
西田洋
河野繁行
丰田晃子
丹泽文惠
藤原康策
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ube Corp
Original Assignee
Ube Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ube Industries Ltd filed Critical Ube Industries Ltd
Publication of CN102482281A publication Critical patent/CN102482281A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2010800334905A 2009-07-28 2010-07-27 吡咯并[2，3-d]嘧啶衍生物 Pending CN102482281A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009175619 2009-07-28
JP2009-175619 2009-07-28
PCT/JP2010/062602 WO2011013656A1 (ja) 2009-07-28 2010-07-27 ピロロ［２，３－ｄ］ピリミジン誘導体

Publications (1)

Publication Number Publication Date
CN102482281A true CN102482281A (zh) 2012-05-30

Family

ID=43529310

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800334905A Pending CN102482281A (zh) 2009-07-28 2010-07-27 吡咯并[2，3-d]嘧啶衍生物

Country Status (10)

Country Link
US (1) US20120149902A1 (enExample)
EP (1) EP2511276A4 (enExample)
JP (1) JPWO2011013656A1 (enExample)
KR (1) KR20120065321A (enExample)
CN (1) CN102482281A (enExample)
AU (1) AU2010279188A1 (enExample)
CA (1) CA2768821A1 (enExample)
IN (1) IN2012DN01251A (enExample)
TW (1) TW201107328A (enExample)
WO (1) WO2011013656A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109937038A (zh) * 2016-08-26 2019-06-25 田边三菱制药株式会社 双环式含氮杂环化合物
CN109952306A (zh) * 2016-04-19 2019-06-28 加利福尼亚大学董事会 ErbB抑制剂及其用途
CN113277990A (zh) * 2021-06-22 2021-08-20 仪征市海帆化工有限公司 一种1,4-双(对甲苯磺酰基)三氮环壬烷的合成方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104781260A (zh) * 2012-09-26 2015-07-15 拜耳制药股份公司 用于治疗过度增殖性障碍的取代的吲唑-吡咯并嘧啶
US20150252047A1 (en) 2012-09-26 2015-09-10 Bayer Pharma Aktiengesellschaft Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseases

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0795556A1 (en) * 1996-02-29 1997-09-17 PHARMACIA & UPJOHN S.p.A. 4-Substituted pyrrolopyrimidine compounds as tyrosin kinase inhibitors
WO1998007726A1 (en) * 1996-08-23 1998-02-26 Novartis Ag Substituted pyrrolopyrimidines and processes for their preparation
CN1194647A (zh) * 1995-07-06 1998-09-30 诺瓦蒂斯有限公司 吡咯并嘧啶及其制备方法
CN1615306A (zh) * 2001-11-14 2005-05-11 布里斯托尔-迈尔斯斯奎布公司 C－5修饰的吲唑基吡咯并三嗪类化合物
WO2006104971A1 (en) * 2005-03-28 2006-10-05 Bristol-Myers Squibb Company Atp competitive kinase inhibitors
CN1922182A (zh) * 2003-12-29 2007-02-28 布里斯托尔-迈尔斯·斯奎布公司 作为激酶抑制剂的吡咯并三嗪化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119249D0 (en) * 2001-08-07 2001-10-03 Novartis Ag Organic compounds

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1194647A (zh) * 1995-07-06 1998-09-30 诺瓦蒂斯有限公司 吡咯并嘧啶及其制备方法
EP0795556A1 (en) * 1996-02-29 1997-09-17 PHARMACIA & UPJOHN S.p.A. 4-Substituted pyrrolopyrimidine compounds as tyrosin kinase inhibitors
WO1998007726A1 (en) * 1996-08-23 1998-02-26 Novartis Ag Substituted pyrrolopyrimidines and processes for their preparation
CN1615306A (zh) * 2001-11-14 2005-05-11 布里斯托尔-迈尔斯斯奎布公司 C－5修饰的吲唑基吡咯并三嗪类化合物
CN1922182A (zh) * 2003-12-29 2007-02-28 布里斯托尔-迈尔斯·斯奎布公司 作为激酶抑制剂的吡咯并三嗪化合物
WO2006104971A1 (en) * 2005-03-28 2006-10-05 Bristol-Myers Squibb Company Atp competitive kinase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PETER M.TRAXLER，等: "4-(Phenylamino)pyrrolopyrimidines: Potent and Selective, ATP Site Directed Inhibitors of the EGF-Receptor Protein Tyrosine Kinase", 《J. MED. CHEM.》 *
彭涛，等: "表皮生长因子受体酪氨酸激酶抑制剂的药效团研究", 《化学学报》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109952306A (zh) * 2016-04-19 2019-06-28 加利福尼亚大学董事会 ErbB抑制剂及其用途
CN109937038A (zh) * 2016-08-26 2019-06-25 田边三菱制药株式会社 双环式含氮杂环化合物
CN113277990A (zh) * 2021-06-22 2021-08-20 仪征市海帆化工有限公司 一种1,4-双(对甲苯磺酰基)三氮环壬烷的合成方法

Also Published As

Publication number Publication date
IN2012DN01251A (enExample) 2015-05-15
US20120149902A1 (en) 2012-06-14
CA2768821A1 (en) 2011-02-03
TW201107328A (en) 2011-03-01
WO2011013656A1 (ja) 2011-02-03
EP2511276A1 (en) 2012-10-17
JPWO2011013656A1 (ja) 2013-01-07
KR20120065321A (ko) 2012-06-20
EP2511276A4 (en) 2012-12-19
AU2010279188A1 (en) 2012-02-23

Similar Documents

Publication Publication Date Title
TWI879811B (zh) 作為免疫調節劑之吡啶并[3,2-d]嘧啶化合物
US11136326B2 (en) Pyrrolopyrimidine derivatives as TAM inhibitors
TWI876724B (zh) 作為tam抑制劑之吡咯并三嗪化合物
DK2727918T3 (da) Forbindelser og sammensætninger som proteinkinaseinhibitorer
CA3150681A1 (en) Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
US20220017520A1 (en) Macrocyclic compound as cdk inhibitor, preparation method therefor, and use thereof in medicine
IL279829B1 (en) Fused pyrazine derivatives as A2A/A2B inhibitors
US9840503B2 (en) Heterocyclic compounds and uses thereof
JP7239562B2 (ja) 光学活性な架橋型環状２級アミン誘導体
MX2010013843A (es) Pirazolo-quinazolinas.
TW200835485A (en) Novel aminopyrimidine derivatives as PLK1 inhibitors
AU2012308681A1 (en) Aminopyrimidine derivatives for use as modulators of kinase activity
CA3037998A1 (en) Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
EP4514473B1 (en) Heterocyclic compounds as modulators of bcl6 as ligand directed degraders
US20230203010A1 (en) Bicyclic amine cdk12 inhibitors
CN102482281A (zh) 吡咯并[2，3-d]嘧啶衍生物
KR20110119641A (ko) 프롤린 고리 구조를 갖는 이미다조티아졸 유도체
CA2753304C (en) Tricyclic pyrazolopyrimidine derivatives as hsp inhibitors
CA3194824A1 (en) Covalent egfr inhibitors and methods of use thereof
CA3163959A1 (en) Cyano-pyrimidine inhibitors of egfr/her2
US12037330B2 (en) Heteroaryl derivative compounds, and uses thereof
US20220289733A1 (en) Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component
WO2023107705A1 (en) Bicyclic amines as cdk12 inhibitors
CN110078743A (zh) 用作激酶活性调节剂的新颖的咪唑-哌啶基衍生物
US20260070915A1 (en) Substituted 7h-pyrrolo[2,3-d]pyrimidin-2-amines as selective cdk2/4 inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120530